Three-drug combinations have long represented state-of-the-art antiretroviral therapy for patients living with HIV. The clinical case presented here illustrates key challenges and considerations associated with switching a patient with stable viral control on a commonly used 3DR to the more recent, user-friendly 2-drug regimens.
Special Collections
